Bicara Therapeutics Inc. (BCAX)
| Market Cap | 1.44B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137.95M |
| Shares Out | 65.47M |
| EPS (ttm) | -2.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,915 |
| Open | 22.51 |
| Previous Close | 22.48 |
| Day's Range | 21.82 - 22.76 |
| 52-Week Range | 7.80 - 24.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 28.00 (+27.74%) |
| Earnings Date | May 11, 2026 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BCAX stock is "Buy." The 12-month stock price target is $28.0, which is an increase of 27.74% from the latest price.
News
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...
Bicara Therapeutics Earnings Call Transcript: Q4 2025
Achieved key milestones with FDA breakthrough therapy designation and strong clinical data for ficerafusp alfa, advancing to phase III and securing $161.8M in new funding. Cash runway extends into 2029, supporting regulatory, commercial, and development initiatives.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loadi...
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...
Bicara Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The session highlighted strong clinical activity and durability for a bifunctional EGFR TGF-beta antibody in HPV-negative head and neck cancer, with a 21% complete response rate and robust safety profile. A pivotal phase III trial is underway, and commercial infrastructure is being built for a U.S. launch.
Bicara Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
FICERA, a bifunctional antibody targeting EGFR and TGF-beta, is showing strong efficacy and durability in HPV-negative head and neck cancer, with a pivotal trial progressing globally and FDA support for the 1,500 mg dose. Commercial launch is planned for 2028, with expansion into CRC and PDAC underway.
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Transcript: Study update
Ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows high response rates, deep and durable responses, and a favorable safety profile at both weekly and less frequent dosing. Biomarker and clinical data support a move to a loading/maintenance regimen, with regulatory plans for flexible dosing.
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable respons...
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant clinical progress was made with ficerafusp alfa, including FDA breakthrough designation and strong survival data in HPV-negative head and neck cancer. The pivotal phase III study is underway, with commercial launch targeted for early 2028 and expansion into other solid tumors planned.
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 i...
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Transcript: Status Update
Ficerafusp alfa plus pembrolizumab shows high response rates and manageable safety in HPV-negative HNSCC, with deeper and more durable responses at the 1,500 mg dose. Dose selection for the pivotal FORTIFY-HN01 trial is expected in Q1 2026, with data supporting the higher dose.
Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study i...
Bicara Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Ficerafusp alfa has shown significant improvements in response and survival for head and neck cancer, with both 750 mg and 1,500 mg doses under evaluation. The pivotal trial uses a seamless design for potential accelerated approval, and less frequent dosing is being explored to enhance patient convenience.
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selecti...
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alf...
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC Designation supported by results from multiple dose cohorts from t...
Bicara Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Ficerafusp alfa, a bifunctional EGFR-TGF-β1/3 inhibitor, is showing strong efficacy in HPV-negative head and neck cancer, with pivotal trials on track and a robust regulatory and commercial strategy. The program is well-funded, expanding into additional indications, and leveraging AI for development.
Bicara Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Lead EGFR TGF-beta bifunctional shows strong survival benefit in head and neck cancer, with pivotal trials underway and expansion into colorectal and locally advanced settings planned. Dose optimization and companion diagnostics are advancing, with robust funding supporting operations through 2029.
Bicara Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Ficerafusp alfa, a bispecific EGFR/TGF-beta inhibitor, is showing promising efficacy and durability in HPV-negative head and neck cancer, with pivotal trial milestones and dose selection expected in the next year. The program is well-funded and aims to set a new standard of care.